Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy

Therapeutic options for Alzheimer’s disease remain limited. In this cutting-edge study, Chen Y et al. employed anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) as a novel immunotherapy, demonstrating reduced amyloid burden and related pathology following plaque formation, and preventing early plaque deposition in vivo via coordinated astrocyte–microglia interactions. The foregoing findings position CAR engineering as a scalable and tunable strategy as a future option for the treatment of neurodegenerative diseases.